RIÑÓN Y ENFERMEDAD CARDIOVASCULAR - Seden

BIBLIOGRAFÍA
Diabetes Complications Study. Diabetes Care 24: 1053-
1059, 2001
840. Kohler KA, Mc Clellan WM, Ziemer DC, Kleinbaum DG,
Boring JR.Risk factors for microalbuminuria in black
Americans with newly diagnosed type 2 diabetes. Am J
Kidney Dis 36: 903-913, 2000
841. Font J, Ramos-Casals M, Cervera R, Garcia-Carrasco M,
Torras A, Siso A y cols. Cardiovascular risk factors and the
long term outcome of lupus nephritis. QJM 94: 19-26, 2001
842. Manttari M, Tiula E, Alikoski T, Manninen V.Effects of hypertension
and dyslipidemia on the decline in renal function.
Hypertension 26: 670-675, 1995
843. Nielsen S, Schmitz A, Rehling A, Mogensen CE.The clinical
course of renal function I NIDDM patients with normo and
microalbuminuria. J Intern Med 241: 133-141, 1997
844. Cappelli P, Liberato L, Albertazzi A. Role of dyslipidemia in
the progression of chronic renal disease. Ren Fail 20: 391-
397, 1998
845. Gall MA, Nielsen FS, Smidt UM, Parving HH. The course of
kidney function in type 2 (non insulin dependent) diabetic
patients with diabetic nephropathy. Diabetologia 36: 1071-
1078, 1993
846. Crook ED, Thallapureddy A, Migdal S, Flack JM, Greene EL,
Salahudeen A y cols. Lipid abnormalities and renal disease:
is Dyslipidemia a predictor of progression of renal disease?
Am J Med Sci 325(6): 340-348, 2003
847. Wanner C, Krane V. Uremia specific alterations in lipid metabolism.
Blood Purificat 20: 451-453, 2002
848. Kronenberg F, Neyer U, Lhotta K, Trenkwalder E, Auinger M,
Pribasnig A y cols. The low molecular weight apo(a) phenotype
is an independent predictor for coronary artery disease
in hemodialysis patient: A prospective follow up. J Am
Soc Nephrol 10: 1027-1036, 1999
849. Iseki K, Uehara H, Nishime K, Tokuyama K, Yoshihara K,
Kinjo K, y cols. Impact of the initial levels of laboratory
variables on survival in chronic dialysis patients. Am J
Kidney Dis 28: 541-548, 1996
850. Koda Y, Nishi S, Suzuki M, Hirasawa Y. Lipoprotein(a) is a
predictor for cardiovascular mortality of hemodialysis
patients. Kidney Int (Suppl 71): S251-S253,1999
851. Fujisawa M, Haramaki R, Miyazaki H, Imaizumi T, Okuda S.
Role of lipoprotein(a) and TGF-beta1 in atherosclerosis of
hemodialysis patients. J Am Soc Nephrol 11: 1889-1895,
2000
852. Longenecker JC, Coresh J, Marcovina SM, Powe NR, Levey
AS, Giaculli Fy cols. Lipoprotein(a) and prevalent cardiovascular
disease in a dialysis population: the choices for healthy
outcomes in caring for ESRD (CHOICE) study. Am J Kidney
Dis 42: 108-116, 2003
853. Koch M, Kutkuhn H, Trenkwalder E, Ritz E. Apolipoprotein
B, fibrinogen, HDL cholesterol, and apolipoprotein(a), phenotypes
predict coronary artery disease in hemodialysis
patients. J Am Soc Nephrol 8: 1889-1898, 1997
854. Nishizawa Y, Shoji T, Kakiya R, Tsujimoto Y, Tabata T,
Ishimura E y cols. Non high density lipoprotein cholesterol
(non-HDL-C) as a predictor of cardiovascular mortality in
patients with end stage renal disease. Kidney Int 63(suppl
84): S117-S120, 2003
855. Kates DM,Haas L, Brunzell J, Sherrard DJ. Risk factors for
cardiovascular disease in end stage renal failure patients. A
21 year study. J Am Soc Nephrol 6: 540 (abstract), 1995
856. Tschope W; Koch M Thomas B, Ritz E. Serum lipids predict
cardiac death in diabetic patients on maintenance hemodialysis.
Results of a prospective study. The German Study
Group Diabetes and Uremia. Nephron 64: 354-358, 1993
857. Shoji T, Kimoto E, Shinohara K, Emoto M, Ishimura E, Miki T
y cols. The association of antibodies against oxidized lowdensity
lipoprotein with atherosclerosis in hemodialysis
patients. Kidney Int 63(suppl 84): S128-S130, 2003
858. Bairaktari E, Elisaf M, Tzallas C, Karabina SA, Tselepis AD,
Siamopoulos KC y cols. Evaluation of five methods for determining
low density lipoprotein cholesterol (LDL-C) in hemodialysis
patients. Clin Biochem 34: 593-602, 2001
859. Smith SC Jr, Blair SN, Bonow RO, y cols. AHA/ACC Scientific
Statement: AHA/ACC guidelines for preventing heart attack
an death in patients with atherosclerotic cardiovascular disease:
2001 update: A statement for healthcare professionals
from the American Heart Association and the American
College of Cardiology. Circulation 104: 1577-1579, 2001.
860. Nauck M, Kramer-Guth A, Bartens W, Marz W, Wieland H,
Wanner C. Is the determination of LDL cholesterol according
to Fridewald accurate in CAPD and HD patients? Clin
Nephrol 46: 319-325, 1996
861. Hirsch GA, Vaid N, Blumenthal RS. Perspectives: The significance
of measuring non-HDL-cholesterol. Prev Cardiol 5:
156-159, 2002
862. Lu W. Non-HDL cholesterol as a predictor of cardiovascular
disease in type 2 diabetes: The strong heart study. Diabetes
Care 26: 240-242, 2003.
863. Shoji T, Nishizawa Y, Kawagishi T, Kawasaki K, Taniwaki H,
Tabata T, y cols. Intermediate density lipoprotein as an independent
risk factor for aortic atherosclerosis in hemodialysis
patients. J Am Soc Nephrol 9: 1277-1284, 1998
864. Shoji T, Ishimura E, Inaba M, Tabata T, Nishizawa Y.
Atherogenic lipoproteins in end stage renal disease. Am J
Kidney Dis 38 (suppl 1): S30-S33, 2001
865. Belani S, Goldberg A, Coyne D. Ability of non-high-density
lipoprotein cholesterol and calculated intermediate density
lipoprotein to identify non-traditional lipoprotein subclass
risk factors in dialysis patients. Am J Kidney Dis 43: 320-
329, 2004.
866. Lowrie EG, Lew NL. Death risk in hemodialysis patients: the
predictive value of commonly measured variables and an
evaluation of death rate differences between facilities. Am J
Kidney Dis 25: 458-482, 1990
867. Iseki K, Yamazato M, Tozawa M, Takishita S. Hypocholesterolemia
is a significant predictor of death in the cohort of
chronic hemodialysis patients. Kidney Int 61:1887-1893, 2002
868. Webb AT, Brown EA. Prevalence of symptomatic arterial
disease and risk factors for its development in patients on
continous ambulatory peritoneal dialysis. Perit Dial Int 13
(suppl 2): S406-S408, 1993
869. Olivares J, Cruz C, Gas JM, Prados MC, Perdiguero M,
Caparros G, y cols. Evolution of lipid profiles in long term
peritoneal dialysis. Adv Perit Dial 8: 373-375, 1992
870. Kronenberg F, Stühlinger M, Trenkwalder E, Geethanjali FS,
Pachinger O, von Eckardstein A, y cols. Low apolipoprotein
A-IV plasma concentrations in men with coronary artery
disease. J Am Coll Cardiol 36: 751-757, 2000
871. Kronenberg F, Kuen E, Ritz E, Konig P, Kraatz G, Lhotta K y
cols. Apolipoprotein A-IV serum concentrations are elevated
in mild and moderate renal failure. J Am Soc Nephrol 13:
461-469, 2002
213